Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05172570 · ClinicalTrials.gov registry record · Phase 3
Gabapentin Dosages for Postoperative Analgesia Following Open Thoracotomy
A Phase 3 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT05172570 is a Phase 3 study that was terminated before completion, run by Indiana University. The registered enrollment target is 20 participants.
The verdict
NCT05172570, a Phase 3 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
Gabapentin is a nerve medication that treats pain. The specific aim of the study is to compare the difference in the postoperative use of no gabapentin, 300 mg gabapentin 3x daily, or 300 mg gabapentin once at night. Our hypothesis is that higher doses of gabapentin will correlate with decreased pain at the incision and chest tube sites and decreased opioid consumption.
Interventions
- DRUG Gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-04-06 |
| Est. Completion | 2022-03-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05172570
The ClinicalTrials.gov registry entry for NCT05172570 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gabapentin is the first listed.
NCT05172570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05172570 about?
NCT05172570 is a clinical study titled "Gabapentin Dosages for Postoperative Analgesia Following Open Thoracotomy". Gabapentin is a nerve medication that treats pain. The specific aim of the study is to compare the difference in the postoperative use of no gabapentin, 300 mg gabapentin 3x daily, or 300 mg gabapentin once at night. Our hypothesis is that higher doses of gabapentin will correlate with decreased pai...
What is the current status of trial NCT05172570?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2021-04-06. Estimated completion is 2022-03-02.
What interventions are being tested in trial NCT05172570?
The interventions under investigation include: Gabapentin (DRUG).
Who is sponsoring clinical trial NCT05172570?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.